Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics on the NYSE (TGX) -- Ignore unavailable to you. Want to Upgrade?

To: dfloydr who wrote (290)	1/14/2000 1:17:00 AM
From: dfloydr	Read Replies (2) \| Respond to of 305

Ron, this board has turned into a private chat room for you and me it is so quiet. Over on Yahoo there has been a lot of chatter about new competition along with the usual tripe about lousy management etc.. I did a nickel's worth of research on two of the new competitors and responded as follows: IMX and UroCor thoughts. by: dfloydr (M/Scottsdale, AZ) 1/14/00 1:06 am EST Competition has to start somewhere, it is true, but looking over the financials of these two new players and all their news releases, I detect that, so far, these two are selling vapor ware and press releases. Now that can change ... in a lot of ways. Remember how TGX/Indigo stumbled when Indigo ignored TGX and went off trying to sell their product to the urologists .... as UroCor and IMX say they intend to do. It has taken large ad budgets directed at the patient to get TGX where it is today and more recently to get sales back on track. I suspect the TGX/Indigo ad campaign costs more than either of these companies have to spend in total, and each of these are tiny and in several other businesses that could demand cash at any time. That is not to say that they might not piggy back on TGX/Indigo's advertising coat tails ... but then they may not. They also might do well through their connections with hospital purchasing departments. But nowadays the large hospital purchasing agent's job mission is to hammer the hell out of supplier's margins. Both of these players might just find that they are a bit late for this party. Many times in many product lines I have seen the me-too makers flood in and then evaporate. How much would you invest in a new Cola company or Hamburger chain or a new computer box maker? I also note that IMX uses a "dry" technique allowing a large inventory. What use is a large inventory to a doc or a patient. It is just a cost to the producer. UCOR talks about distribution points and a lot handling features that look like time wasting delay points. By the time a product made it through that kind of distribution its half life would be over. And which point would be responsible for what? Each seed should be accountable all the way back to inception and with two or three or four intermediaries, who do I sue or blame or scream at? I wonder what Therapy Dr. might know about these two? The docs I have spoken to like reliable quality and prompt distribution. TGX gives that, as does Amersham. The rest have yet to prove themselves ... you want to be the doc to try them?